1. Home
  2. ENSG vs CORT Comparison

ENSG vs CORT Comparison

Compare ENSG & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Ensign Group Inc.

ENSG

The Ensign Group Inc.

SELL

Current Price

$176.23

Market Cap

10.4B

Sector

Health Care

ML Signal

SELL

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

SELL

Current Price

$109.87

Market Cap

9.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ENSG
CORT
Founded
1999
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
9.7B
IPO Year
2007
2001

Fundamental Metrics

Financial Performance
Metric
ENSG
CORT
Price
$176.23
$109.87
Analyst Decision
Buy
Buy
Analyst Count
5
5
Target Price
★ $220.00
$141.00
AVG Volume (30 Days)
307.1K
★ 1.3M
Earning Date
11-02-2026
11-03-2026
Dividend Yield
★ 0.15%
N/A
EPS Growth
★ 14.06
N/A
EPS
★ 3.35
0.09
Revenue
★ $5,057,841,000.00
$761,407,000.00
Revenue This Year
$16.75
$50.53
Revenue Next Year
$11.19
$48.90
P/E Ratio
★ $53.21
$1,260.89
Revenue Growth
★ 18.72
12.79
52 Week Low
$141.58
$28.66
52 Week High
$218.00
$126.38

Technical Indicators

Market Signals
Indicator
ENSG
CORT
Relative Strength Index (RSI) 56.04 39.75
Support Level $167.52 $108.33
Resistance Level $177.49 $122.96
Average True Range (ATR) 3.46 4.83
MACD 0.65 -0.92
Stochastic Oscillator 72.63 12.18

Price Performance

Historical Comparison
ENSG
CORT

About ENSG The Ensign Group Inc.

Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: